Bio Pharma Dive
OCTOBER 7, 2024
The Cambridge, Massachusetts-based biotech is using what it calls ligand-siRNA conjugates to reach drug targets in the kidney, which historically have been difficult to reach with RNA therapies.
Deltaclinical
OCTOBER 7, 2024
Would you like to learn more about our services? Visit us at booth C-24. We are happy to welcome you! But first, our CEO Geert Briers will attend the EU-Japan center conference in Osaka from 7 – 8 OCT.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
OCTOBER 7, 2024
Health Canada has expanded the approved use of Telix Pharmaceuticals' Illuccix for patient selection in PSMA targeted radionuclide therapy.
pharmaphorum
OCTOBER 7, 2024
The recent Mpox outbreak highlights the urgent need for new approaches to therapeutic antibody research. Discover how the World Health Organization (WHO) and CDC are responding to this public health crisis.
Bio Pharma Dive
OCTOBER 7, 2024
The study, of Intellia’s treatment for hereditary angioedema, is the second Phase 3 trial the biotech has begun testing its “in vivo” gene editing medicines.
Drug Discovery World
OCTOBER 7, 2024
DDW’s Diana Spencer explores some of North America’s most important life science hubs and finds out the benefits of each unique ecosystem. The United States dominates the biotech sector in North America and globally, with an estimated value share of nearly 59% in 2021 1. According to Key Biotechnology Indicators collated by the Organisation for Economic Co-operation and Development (OECD), the country had the largest number of biotechnology firms in 2021 with 2,840 2 , though some sources say th
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
pharmaphorum
OCTOBER 7, 2024
UK Health Secretary Wes Streeting has announced plans to allow NHS England to share primary care data with scientific researchers, taking on some of the responsibility held by GPs. The minister told the Royal College of General Practitioners (RCGP) annual conference that, while many UK patients have given their consent for their data to be shared with studies run by the likes of the UK Biobank, Genomics England, and Our Future Health, they "still see, far too often, that this data is not shared
Bio Pharma Dive
OCTOBER 7, 2024
Phase 3 findings could position the biotech’s therapy to become part of a “new standard” for SMA, its CEO said, while boosting research into whether it can preserve muscle in people with obesity.
Drug Patent Watch
OCTOBER 5, 2024
NUCYNTA ER (tapentadol hydrochloride) Collegium pharm inc Patent: 8,114,383 Expiration: Oct 10, 2024 See More … Source
Pharmaceutical Technology
OCTOBER 7, 2024
The safety review was requested by the French medicines agency, citing new safety reports that alter the risk profile of finasteride.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
pharmaphorum
OCTOBER 6, 2024
Activist investor Starboard Value has amassed a $1bn stake in pharma group Pfizer and wants strategic changes to restore growth
Bio Pharma Dive
OCTOBER 7, 2024
The development of cancer vaccines has provided some hope in the battle against cancer worldwide; however, there are still many challenges to overcome when developing these life-saving treatments.
Fierce Pharma
OCTOBER 7, 2024
With a new patent settlement, generic partners Mylan and Natco have cleared one hurdle to a potential U.S. launch of their generic to Novo Nordisk's wildly popular Type 2 diabetes drug Ozempic. | Mylan Pharmaceuticals and Novo Nordisk have reached a confidential settlement in a patent lawsuit tied to generic Ozempic, also known as semaglutide, India’s Natco Pharma said.
Pharmaceutical Technology
OCTOBER 7, 2024
The company intends to start a registrational Phase II trial of pelareorep and chemotherapy combination for breast cancer in 2025.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
pharmaphorum
OCTOBER 7, 2024
AstraZeneca pays $100m upfront for rights to an oral lipoprotein(a) drug developed by Chinese biotech CSPC Pharmaceutical.
Bio Pharma Dive
OCTOBER 7, 2024
Producing safe, effective, high-quality viral vector therapeutics depends on a robust and tailored analytical testing strategy.
Fierce Pharma
OCTOBER 7, 2024
GSK’s ViiV healthcare unit is countering rival HIV drugmaker Gilead’s recent global access moves with its own pledge to make at least 2 million doses of its long-acting pre-exposure prophylaxis (Pr | The long-acting HIV PrEP maker pledged to make at least 2 million more doses available for low-and middle-income countries in 2025 and 2026.
Pharmaceutical Technology
OCTOBER 7, 2024
US hedge fund Starboard now holds 0.6% of Pfizer’s value as the drugmaker struggles with its post-pandemic financial performance.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Drug Discovery World
OCTOBER 7, 2024
In this Case Study, InSphero, a Swiss-based company specialising in 3D in vitro cell models and cell culture tools for drug discovery, describes: The advantages of 3D in vitro cell models for drug discovery The automation of the production of 3D in vitro cell models via InSphero’s Akura™ technology The benefits of InSphero’s Akura™ technology and Hamilton’s pipetting technologies The post Enhancing Scalability and Quality of 3D In Vitro Cell Models Production through Automation appeared first on
Intouch Solutions
OCTOBER 7, 2024
How does your organization make marketing decisions? Artificial intelligence (AI) is revolutionizing the way pharmaceutical companies make marketing decisions, and EVERSANA INTOUCH is at the forefront of this transformation. In this POV, John Kenny, EVP and Head of Strategic Planning, delves into the innovative use of AI-powered personas to keep the customer’s perspective central in marketing strategies.
XTalks
OCTOBER 7, 2024
Real-world evidence (RWE) is gaining increasing interest in the pharmaceutical industry, particularly in enhancing drug approval processes and optimizing clinical trial designs. Kelly Brassil, PhD, RN, FAAN Senior Director, Business Development Pack Health, a Quest Diagnostics company RWE is being used to expand drug labels to include broader patient populations often underrepresented in traditional studies.
Pharmaceutical Technology
OCTOBER 7, 2024
The CD7 CAR)-T cell therapy has demonstrated potential in treating patients with relapsed or refractory T-cell leukaemia.
Drug Discovery World
OCTOBER 7, 2024
Download this new Case Study from Hamilton and InSphero, entitled ‘ Enhancing Scalability and Quality of 3D In Vitro Cell Models Production through Automation ‘ In this Case Study, InSphero, a Swiss-based company specialising in 3D in vitro cell models and cell culture tools for drug discovery, describes: The advantages of 3D in vitro cell models for drug discovery The automation of the production of 3D in vitro cell models via InSphero’s Akura technology The benefits of InSphero’s A
Pharmaceutical Commerce
OCTOBER 7, 2024
In the final part of her video interview with Pharma Commerce Editor Nicholas Saraceno, Jenni Zilka, SVP, community & specialty pharmacy and president, Good Neighbor Pharmacy, explains how pending legislation can improve patient access, and how these are helping with recognizing pharmacists as HCPs.
Fierce Pharma
OCTOBER 7, 2024
After Kaléo unveiled a “redesign” of the in-office commercial team for its EpiPen rival Auvi-Q at the start of the month, the privately held company has announced a fresh round of job cuts in the U | After Kaléo unveiled a “redesign” of the in-office commercial team for its EpiPen rival Auvi-Q at the start of the month, the privately held company has announced a fresh round of job cuts across the U.S.
Pharmaceutical Technology
OCTOBER 7, 2024
OnKure has announced the successful completion of its merger with Reneo Pharmaceuticals, forming the combined entity
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Drug Discovery World
OCTOBER 7, 2024
The European Commission has conditionally approved Iqirvo (elafibranor) 80mg tablets for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA). The approval is limited to adults with an inadequate response to UDCA or as a monotherapy in patients unable to tolerate UDCA. Iqirvo is a first-in-class, oral, peroxisome proliferator-activated receptor (PPAR) agonist, that exerts an effect on the proteins PPARα and PPARδ, thought to be key regulators of bile
Drug Channels
OCTOBER 7, 2024
Informa Connect’s PBM Contracting Summit December 10-11, 2024 | Chicago, IL Drug Channels readers save 10% with code 24DRCH10 * Experts from across the US come together each year at the PBM Contracting Summit to gain innovative and practical contracting strategies, master PBM innovation and design, improve patient care management and rising costs, understand the current legislative issues impacting contract negotiations and more.
pharmaphorum
OCTOBER 7, 2024
Stay updated on the latest advancements in early detection and innovative therapies targeting tau pathology in Alzheimer’s disease. Learn more about the cutting-edge research and treatments available.
Pharmaceutical Technology
OCTOBER 7, 2024
ProductLife Group (PLG) has announced the acquisition of IntiQuan, a Swiss firm specialising in pharmacometrics.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Expert insights. Personalized for you.
246 
Let's personalize your content